Click for best price
Postmenopausal Vaginal Atrophy Drugs Market Size, Share 2024
The global Postmenopausal Vaginal Atrophy Drugs market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is Forecast to Reach $ Million.
Topical Estrogen Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Postmenopausal Vaginal Atrophy Drugs include Pfizer Inc, Mylan NV, Novartis AG, Hikma Pharmaceuticals plc, Aurobindo Pharma, AbbVie Inc, Melinta Therapeutics, Inc, Bristol-Myers Squibb Company and GSK plc, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
Postmenopausal vaginal atrophy (PVA) is the type of condition of vaginal wall thinning the reduced level of estrogen causes that. The changes in the genitourinary tract arising from a hypoestrogenic state includes decreased vaginal vascularization, reduced vaginal lubrication, thinning of the vaginal epithelium. The pH level continuously increases and loss of lactobacilli microflora allows opportunistic colonization by pathogenic bacteria can produce infection.
This report aims to provide a comprehensive presentation of the global market for Postmenopausal Vaginal Atrophy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Postmenopausal Vaginal Atrophy Drugs. This report contains market size and forecasts of Postmenopausal Vaginal Atrophy Drugs in global, including the following market information:
Global Postmenopausal Vaginal Atrophy Drugs Market Revenue, 2020-2024, 2025-2030, ($ millions)
Global Postmenopausal Vaginal Atrophy Drugs Market Sales, 2020-2024, 2025-2030, (K Units)
Global top five Postmenopausal Vaginal Atrophy Drugs companies in 2023 (%)
We surveyed the Postmenopausal Vaginal Atrophy Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Postmenopausal Vaginal Atrophy Drugs Market, by Type, 2020-2024, 2025-2030 ($ Millions) & (K Units)
Global Postmenopausal Vaginal Atrophy Drugs Market Segment Percentages, by Type, 2023 (%)
Topical Estrogen
Oral Estrogen
Other
Global Postmenopausal Vaginal Atrophy Drugs Market, by Application, 2020-2024, 2025-2030 ($ Millions) & (K Units)
Global Postmenopausal Vaginal Atrophy Drugs Market Segment Percentages, by Application, 2023 (%)
Online Pharmacy
Hospital Pharmacy
Global Postmenopausal Vaginal Atrophy Drugs Market, By Region and Country, 2020-2024, 2025-2030 ($ Millions) & (K Units)
Global Postmenopausal Vaginal Atrophy Drugs Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Postmenopausal Vaginal Atrophy Drugs revenues in global market, 2020-2024 (Estimated), ($ millions)
Key companies Postmenopausal Vaginal Atrophy Drugs revenues share in global market, 2023 (%)
Key companies Postmenopausal Vaginal Atrophy Drugs sales in global market, 2020-2024 (Estimated), (K Units)
Key companies Postmenopausal Vaginal Atrophy Drugs sales share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer Inc
Mylan NV
Novartis AG
Hikma Pharmaceuticals plc
Aurobindo Pharma
AbbVie Inc
Melinta Therapeutics, Inc
Bristol-Myers Squibb Company
GSK plc
Bayer AG
Lupin
Perrigo Company plc
Bionovo, Inc
TherapeuticsMD, Inc
Endoceutics, Inc
Outline of Major Chapters:
Chapter 1: Introduces the definition of Postmenopausal Vaginal Atrophy Drugs, market overview.
Chapter 2: Global Postmenopausal Vaginal Atrophy Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Postmenopausal Vaginal Atrophy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Postmenopausal Vaginal Atrophy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Postmenopausal Vaginal Atrophy Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Postmenopausal Vaginal Atrophy Drugs Market, Global Outlook and Forecast 2024-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
115 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Postmenopausal Vaginal Atrophy Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Postmenopausal Vaginal Atrophy Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Postmenopausal Vaginal Atrophy Drugs Overall Market Size
2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size: 2023 VS 2030
2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue, Prospects & Forecasts: 2020-2030
2.3 Global Postmenopausal Vaginal Atrophy Drugs Sales: 2020-2030
3 Company Landscape
3.1 Top Postmenopausal Vaginal Atrophy Drugs Players in Global Market
3.2 Top Global Postmenopausal Vaginal Atrophy Drugs Companies Ranked by Revenue
3.3 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Companies
3.4 Global Postmenopausal Vaginal Atrophy Drugs Sales by Companies
3.5 Global Postmenopausal Vaginal Atrophy Drugs Price by Manufacturer (2020-2024)
3.6 Top 3 and Top 5 Postmenopausal Vaginal Atrophy Drugs Companies in Global Market, by Revenue in 2023
3.7 Global Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Postmenopausal Vaginal Atrophy Drugs Players in Global Market
3.8.1 List of Global Tier 1 Postmenopausal Vaginal Atrophy Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Postmenopausal Vaginal Atrophy Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Postmenopausal Vaginal Atrophy Drugs Market Size Markets, 2023 & 2030
4.1.2 Topical Estrogen
4.1.3 Oral Estrogen
4.1.4 Other
4.2 By Type - Global Postmenopausal Vaginal Atrophy Drugs Revenue & Forecasts
4.2.1 By Type - Global Postmenopausal Vaginal Atrophy Drugs Revenue, 2020-2024
4.2.2 By Type - Global Postmenopausal Vaginal Atrophy Drugs Revenue, 2025-2030
4.2.3 By Type - Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2020-2030
4.3 By Type - Global Postmenopausal Vaginal Atrophy Drugs Sales & Forecasts
4.3.1 By Type - Global Postmenopausal Vaginal Atrophy Drugs Sales, 2020-2024
4.3.2 By Type - Global Postmenopausal Vaginal Atrophy Drugs Sales, 2025-2030
4.3.3 By Type - Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share, 2020-2030
4.4 By Type - Global Postmenopausal Vaginal Atrophy Drugs Price (Manufacturers Selling Prices), 2020-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Postmenopausal Vaginal Atrophy Drugs Market Size, 2023 & 2030
5.1.2 Online Pharmacy
5.1.3 Hospital Pharmacy
5.2 By Application - Global Postmenopausal Vaginal Atrophy Drugs Revenue & Forecasts
5.2.1 By Application - Global Postmenopausal Vaginal Atrophy Drugs Revenue, 2020-2024
5.2.2 By Application - Global Postmenopausal Vaginal Atrophy Drugs Revenue, 2025-2030
5.2.3 By Application - Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2020-2030
5.3 By Application - Global Postmenopausal Vaginal Atrophy Drugs Sales & Forecasts
5.3.1 By Application - Global Postmenopausal Vaginal Atrophy Drugs Sales, 2020-2024
5.3.2 By Application - Global Postmenopausal Vaginal Atrophy Drugs Sales, 2025-2030
5.3.3 By Application - Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share, 2020-2030
5.4 By Application - Global Postmenopausal Vaginal Atrophy Drugs Price (Manufacturers Selling Prices), 2020-2030
6 Sights by Region
6.1 By Region - Global Postmenopausal Vaginal Atrophy Drugs Market Size, 2023 & 2030
6.2 By Region - Global Postmenopausal Vaginal Atrophy Drugs Revenue & Forecasts
6.2.1 By Region - Global Postmenopausal Vaginal Atrophy Drugs Revenue, 2020-2024
6.2.2 By Region - Global Postmenopausal Vaginal Atrophy Drugs Revenue, 2025-2030
6.2.3 By Region - Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2020-2030
6.3 By Region - Global Postmenopausal Vaginal Atrophy Drugs Sales & Forecasts
6.3.1 By Region - Global Postmenopausal Vaginal Atrophy Drugs Sales, 2020-2024
6.3.2 By Region - Global Postmenopausal Vaginal Atrophy Drugs Sales, 2025-2030
6.3.3 By Region - Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share, 2020-2030
6.4 North America
6.4.1 By Country - North America Postmenopausal Vaginal Atrophy Drugs Revenue, 2020-2030
6.4.2 By Country - North America Postmenopausal Vaginal Atrophy Drugs Sales, 2020-2030
6.4.3 US Postmenopausal Vaginal Atrophy Drugs Market Size, 2020-2030
6.4.4 Canada Postmenopausal Vaginal Atrophy Drugs Market Size, 2020-2030
6.4.5 Mexico Postmenopausal Vaginal Atrophy Drugs Market Size, 2020-2030
6.5 Europe
6.5.1 By Country - Europe Postmenopausal Vaginal Atrophy Drugs Revenue, 2020-2030
6.5.2 By Country - Europe Postmenopausal Vaginal Atrophy Drugs Sales, 2020-2030
6.5.3 Germany Postmenopausal Vaginal Atrophy Drugs Market Size, 2020-2030
6.5.4 France Postmenopausal Vaginal Atrophy Drugs Market Size, 2020-2030
6.5.5 U.K. Postmenopausal Vaginal Atrophy Drugs Market Size, 2020-2030
6.5.6 Italy Postmenopausal Vaginal Atrophy Drugs Market Size, 2020-2030
6.5.7 Russia Postmenopausal Vaginal Atrophy Drugs Market Size, 2020-2030
6.5.8 Nordic Countries Postmenopausal Vaginal Atrophy Drugs Market Size, 2020-2030
6.5.9 Benelux Postmenopausal Vaginal Atrophy Drugs Market Size, 2020-2030
6.6 Asia
6.6.1 By Region - Asia Postmenopausal Vaginal Atrophy Drugs Revenue, 2020-2030
6.6.2 By Region - Asia Postmenopausal Vaginal Atrophy Drugs Sales, 2020-2030
6.6.3 China Postmenopausal Vaginal Atrophy Drugs Market Size, 2020-2030
6.6.4 Japan Postmenopausal Vaginal Atrophy Drugs Market Size, 2020-2030
6.6.5 South Korea Postmenopausal Vaginal Atrophy Drugs Market Size, 2020-2030
6.6.6 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Market Size, 2020-2030
6.6.7 India Postmenopausal Vaginal Atrophy Drugs Market Size, 2020-2030
6.7 South America
6.7.1 By Country - South America Postmenopausal Vaginal Atrophy Drugs Revenue, 2020-2030
6.7.2 By Country - South America Postmenopausal Vaginal Atrophy Drugs Sales, 2020-2030
6.7.3 Brazil Postmenopausal Vaginal Atrophy Drugs Market Size, 2020-2030
6.7.4 Argentina Postmenopausal Vaginal Atrophy Drugs Market Size, 2020-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Revenue, 2020-2030
6.8.2 By Country - Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales, 2020-2030
6.8.3 Turkey Postmenopausal Vaginal Atrophy Drugs Market Size, 2020-2030
6.8.4 Israel Postmenopausal Vaginal Atrophy Drugs Market Size, 2020-2030
6.8.5 Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Market Size, 2020-2030
6.8.6 UAE Postmenopausal Vaginal Atrophy Drugs Market Size, 2020-2030
7 Manufacturers & Brands Profiles
7.1 Pfizer Inc
7.1.1 Pfizer Inc Company Summary
7.1.2 Pfizer Inc Business Overview
7.1.3 Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.1.4 Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2020-2024)
7.1.5 Pfizer Inc Key News & Latest Developments
7.2 Mylan NV
7.2.1 Mylan NV Company Summary
7.2.2 Mylan NV Business Overview
7.2.3 Mylan NV Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.2.4 Mylan NV Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2020-2024)
7.2.5 Mylan NV Key News & Latest Developments
7.3 Novartis AG
7.3.1 Novartis AG Company Summary
7.3.2 Novartis AG Business Overview
7.3.3 Novartis AG Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.3.4 Novartis AG Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2020-2024)
7.3.5 Novartis AG Key News & Latest Developments
7.4 Hikma Pharmaceuticals plc
7.4.1 Hikma Pharmaceuticals plc Company Summary
7.4.2 Hikma Pharmaceuticals plc Business Overview
7.4.3 Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.4.4 Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2020-2024)
7.4.5 Hikma Pharmaceuticals plc Key News & Latest Developments
7.5 Aurobindo Pharma
7.5.1 Aurobindo Pharma Company Summary
7.5.2 Aurobindo Pharma Business Overview
7.5.3 Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.5.4 Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2020-2024)
7.5.5 Aurobindo Pharma Key News & Latest Developments
7.6 AbbVie Inc
7.6.1 AbbVie Inc Company Summary
7.6.2 AbbVie Inc Business Overview
7.6.3 AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.6.4 AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2020-2024)
7.6.5 AbbVie Inc Key News & Latest Developments
7.7 Melinta Therapeutics, Inc
7.7.1 Melinta Therapeutics, Inc Company Summary
7.7.2 Melinta Therapeutics, Inc Business Overview
7.7.3 Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.7.4 Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2020-2024)
7.7.5 Melinta Therapeutics, Inc Key News & Latest Developments
7.8 Bristol-Myers Squibb Company
7.8.1 Bristol-Myers Squibb Company Company Summary
7.8.2 Bristol-Myers Squibb Company Business Overview
7.8.3 Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.8.4 Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2020-2024)
7.8.5 Bristol-Myers Squibb Company Key News & Latest Developments
7.9 GSK plc
7.9.1 GSK plc Company Summary
7.9.2 GSK plc Business Overview
7.9.3 GSK plc Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.9.4 GSK plc Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2020-2024)
7.9.5 GSK plc Key News & Latest Developments
7.10 Bayer AG
7.10.1 Bayer AG Company Summary
7.10.2 Bayer AG Business Overview
7.10.3 Bayer AG Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.10.4 Bayer AG Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2020-2024)
7.10.5 Bayer AG Key News & Latest Developments
7.11 Lupin
7.11.1 Lupin Company Summary
7.11.2 Lupin Postmenopausal Vaginal Atrophy Drugs Business Overview
7.11.3 Lupin Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.11.4 Lupin Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2020-2024)
7.11.5 Lupin Key News & Latest Developments
7.12 Perrigo Company plc
7.12.1 Perrigo Company plc Company Summary
7.12.2 Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Business Overview
7.12.3 Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.12.4 Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2020-2024)
7.12.5 Perrigo Company plc Key News & Latest Developments
7.13 Bionovo, Inc
7.13.1 Bionovo, Inc Company Summary
7.13.2 Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Business Overview
7.13.3 Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.13.4 Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2020-2024)
7.13.5 Bionovo, Inc Key News & Latest Developments
7.14 TherapeuticsMD, Inc
7.14.1 TherapeuticsMD, Inc Company Summary
7.14.2 TherapeuticsMD, Inc Business Overview
7.14.3 TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.14.4 TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2020-2024)
7.14.5 TherapeuticsMD, Inc Key News & Latest Developments
7.15 Endoceutics, Inc
7.15.1 Endoceutics, Inc Company Summary
7.15.2 Endoceutics, Inc Business Overview
7.15.3 Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.15.4 Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2020-2024)
7.15.5 Endoceutics, Inc Key News & Latest Developments
8 Global Postmenopausal Vaginal Atrophy Drugs Production Capacity, Analysis
8.1 Global Postmenopausal Vaginal Atrophy Drugs Production Capacity, 2020-2030
8.2 Postmenopausal Vaginal Atrophy Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Postmenopausal Vaginal Atrophy Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Postmenopausal Vaginal Atrophy Drugs Supply Chain Analysis
10.1 Postmenopausal Vaginal Atrophy Drugs Industry Value Chain
10.2 Postmenopausal Vaginal Atrophy Drugs Upstream Market
10.3 Postmenopausal Vaginal Atrophy Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Postmenopausal Vaginal Atrophy Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Postmenopausal Vaginal Atrophy Drugs in Global Market
Table 2. Top Postmenopausal Vaginal Atrophy Drugs Players in Global Market, Ranking by Revenue (2023)
Table 3. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Companies, (US$, Mn), 2020-2024
Table 4. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Companies, 2020-2024
Table 5. Global Postmenopausal Vaginal Atrophy Drugs Sales by Companies, (K Units), 2020-2024
Table 6. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Companies, 2020-2024
Table 7. Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Price (2020-2024) & (US$/Unit)
Table 8. Global Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
Table 9. List of Global Tier 1 Postmenopausal Vaginal Atrophy Drugs Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Postmenopausal Vaginal Atrophy Drugs Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$, Mn), 2020-2024
Table 13. By Type - Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$, Mn), 2025-2030
Table 14. By Type - Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units), 2020-2024
Table 15. By Type - Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units), 2025-2030
Table 16. By Application ? Global Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2023 & 2030
Table 17. By Application - Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$, Mn), 2020-2024
Table 18. By Application - Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$, Mn), 2025-2030
Table 19. By Application - Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units), 2020-2024
Table 20. By Application - Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units), 2025-2030
Table 21. By Region ? Global Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2023 VS 2030
Table 22. By Region - Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$, Mn), 2020-2024
Table 23. By Region - Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$, Mn), 2025-2030
Table 24. By Region - Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units), 2020-2024
Table 25. By Region - Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units), 2025-2030
Table 26. By Country - North America Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2024
Table 27. By Country - North America Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2025-2030
Table 28. By Country - North America Postmenopausal Vaginal Atrophy Drugs Sales, (K Units), 2020-2024
Table 29. By Country - North America Postmenopausal Vaginal Atrophy Drugs Sales, (K Units), 2025-2030
Table 30. By Country - Europe Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2024
Table 31. By Country - Europe Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2025-2030
Table 32. By Country - Europe Postmenopausal Vaginal Atrophy Drugs Sales, (K Units), 2020-2024
Table 33. By Country - Europe Postmenopausal Vaginal Atrophy Drugs Sales, (K Units), 2025-2030
Table 34. By Region - Asia Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2024
Table 35. By Region - Asia Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2025-2030
Table 36. By Region - Asia Postmenopausal Vaginal Atrophy Drugs Sales, (K Units), 2020-2024
Table 37. By Region - Asia Postmenopausal Vaginal Atrophy Drugs Sales, (K Units), 2025-2030
Table 38. By Country - South America Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2024
Table 39. By Country - South America Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2025-2030
Table 40. By Country - South America Postmenopausal Vaginal Atrophy Drugs Sales, (K Units), 2020-2024
Table 41. By Country - South America Postmenopausal Vaginal Atrophy Drugs Sales, (K Units), 2025-2030
Table 42. By Country - Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2024
Table 43. By Country - Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2025-2030
Table 44. By Country - Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales, (K Units), 2020-2024
Table 45. By Country - Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales, (K Units), 2025-2030
Table 46. Pfizer Inc Company Summary
Table 47. Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 48. Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2020-2024)
Table 49. Pfizer Inc Key News & Latest Developments
Table 50. Mylan NV Company Summary
Table 51. Mylan NV Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 52. Mylan NV Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2020-2024)
Table 53. Mylan NV Key News & Latest Developments
Table 54. Novartis AG Company Summary
Table 55. Novartis AG Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 56. Novartis AG Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2020-2024)
Table 57. Novartis AG Key News & Latest Developments
Table 58. Hikma Pharmaceuticals plc Company Summary
Table 59. Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 60. Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2020-2024)
Table 61. Hikma Pharmaceuticals plc Key News & Latest Developments
Table 62. Aurobindo Pharma Company Summary
Table 63. Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 64. Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2020-2024)
Table 65. Aurobindo Pharma Key News & Latest Developments
Table 66. AbbVie Inc Company Summary
Table 67. AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 68. AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2020-2024)
Table 69. AbbVie Inc Key News & Latest Developments
Table 70. Melinta Therapeutics, Inc Company Summary
Table 71. Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 72. Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2020-2024)
Table 73. Melinta Therapeutics, Inc Key News & Latest Developments
Table 74. Bristol-Myers Squibb Company Company Summary
Table 75. Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 76. Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2020-2024)
Table 77. Bristol-Myers Squibb Company Key News & Latest Developments
Table 78. GSK plc Company Summary
Table 79. GSK plc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 80. GSK plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2020-2024)
Table 81. GSK plc Key News & Latest Developments
Table 82. Bayer AG Company Summary
Table 83. Bayer AG Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 84. Bayer AG Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2020-2024)
Table 85. Bayer AG Key News & Latest Developments
Table 86. Lupin Company Summary
Table 87. Lupin Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 88. Lupin Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2020-2024)
Table 89. Lupin Key News & Latest Developments
Table 90. Perrigo Company plc Company Summary
Table 91. Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 92. Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2020-2024)
Table 93. Perrigo Company plc Key News & Latest Developments
Table 94. Bionovo, Inc Company Summary
Table 95. Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 96. Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2020-2024)
Table 97. Bionovo, Inc Key News & Latest Developments
Table 98. TherapeuticsMD, Inc Company Summary
Table 99. TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 100. TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2020-2024)
Table 101. TherapeuticsMD, Inc Key News & Latest Developments
Table 102. Endoceutics, Inc Company Summary
Table 103. Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 104. Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2020-2024)
Table 105. Endoceutics, Inc Key News & Latest Developments
Table 106. Postmenopausal Vaginal Atrophy Drugs Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2024 (K Units)
Table 107. Global Postmenopausal Vaginal Atrophy Drugs Capacity Market Share of Key Manufacturers, 2021-2024
Table 108. Global Postmenopausal Vaginal Atrophy Drugs Production by Region, 2020-2024 (K Units)
Table 109. Global Postmenopausal Vaginal Atrophy Drugs Production by Region, 2025-2030 (K Units)
Table 110. Postmenopausal Vaginal Atrophy Drugs Market Opportunities & Trends in Global Market
Table 111. Postmenopausal Vaginal Atrophy Drugs Market Drivers in Global Market
Table 112. Postmenopausal Vaginal Atrophy Drugs Market Restraints in Global Market
Table 113. Postmenopausal Vaginal Atrophy Drugs Raw Materials
Table 114. Postmenopausal Vaginal Atrophy Drugs Raw Materials Suppliers in Global Market
Table 115. Typical Postmenopausal Vaginal Atrophy Drugs Downstream
Table 116. Postmenopausal Vaginal Atrophy Drugs Downstream Clients in Global Market
Table 117. Postmenopausal Vaginal Atrophy Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Postmenopausal Vaginal Atrophy Drugs Segment by Type in 2023
Figure 2. Postmenopausal Vaginal Atrophy Drugs Segment by Application in 2023
Figure 3. Global Postmenopausal Vaginal Atrophy Drugs Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Postmenopausal Vaginal Atrophy Drugs Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Postmenopausal Vaginal Atrophy Drugs Revenue, 2020-2030 (US$, Mn)
Figure 7. Postmenopausal Vaginal Atrophy Drugs Sales in Global Market: 2020-2030 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Postmenopausal Vaginal Atrophy Drugs Revenue in 2023
Figure 9. By Type - Global Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2023 & 2030
Figure 10. By Type - Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2020-2030
Figure 11. By Type - Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share, 2020-2030
Figure 12. By Type - Global Postmenopausal Vaginal Atrophy Drugs Price (US$/Unit), 2020-2030
Figure 13. By Application - Global Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2023 & 2030
Figure 14. By Application - Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2020-2030
Figure 15. By Application - Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share, 2020-2030
Figure 16. By Application - Global Postmenopausal Vaginal Atrophy Drugs Price (US$/Unit), 2020-2030
Figure 17. By Region - Global Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2023 & 2030
Figure 18. By Region - Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2020 VS 2023 VS 2030
Figure 19. By Region - Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2020-2030
Figure 20. By Region - Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share, 2020-2030
Figure 21. By Country - North America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2020-2030
Figure 22. By Country - North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share, 2020-2030
Figure 23. US Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2030
Figure 24. Canada Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2030
Figure 25. Mexico Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2030
Figure 26. By Country - Europe Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2020-2030
Figure 27. By Country - Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share, 2020-2030
Figure 28. Germany Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2030
Figure 29. France Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2030
Figure 30. U.K. Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2030
Figure 31. Italy Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2030
Figure 32. Russia Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2030
Figure 33. Nordic Countries Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2030
Figure 34. Benelux Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2030
Figure 35. By Region - Asia Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2020-2030
Figure 36. By Region - Asia Postmenopausal Vaginal Atrophy Drugs Sales Market Share, 2020-2030
Figure 37. China Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2030
Figure 38. Japan Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2030
Figure 39. South Korea Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2030
Figure 40. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2030
Figure 41. India Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2030
Figure 42. By Country - South America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2020-2030
Figure 43. By Country - South America Postmenopausal Vaginal Atrophy Drugs Sales Market Share, 2020-2030
Figure 44. Brazil Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2030
Figure 45. Argentina Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2030
Figure 46. By Country - Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2020-2030
Figure 47. By Country - Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share, 2020-2030
Figure 48. Turkey Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2030
Figure 49. Israel Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2030
Figure 50. Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2030
Figure 51. UAE Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2020-2030
Figure 52. Global Postmenopausal Vaginal Atrophy Drugs Production Capacity (K Units), 2020-2030
Figure 53. The Percentage of Production Postmenopausal Vaginal Atrophy Drugs by Region, 2023 VS 2030
Figure 54. Postmenopausal Vaginal Atrophy Drugs Industry Value Chain
Figure 55. Marketing Channels
